Table 2 Diagnostic performance of HA in the validation set.
HA cut-off | Sensitivity (%) | Specificity (%) | NPV (%) | PPV (%) | Population involved (%) | Interpretation |
|---|---|---|---|---|---|---|
<16 | 91 | 36 | 82 | 55 | 24 | Absence of fibrosis (F0F1) (82% certainty) |
>121 | 14 | 99 | 57 | 94 | 7 | Presence of fibrosis (F2) (94% certainty) |
≤ 25 | 78 | 53 | 89 | 34 | 46 | Absence of severe fibrosis (F0F1F2) (89% certainty) |
>160 | 22 | 100 | 81 | 100 | 5 | Presence of severe fibrosis (F3) (100% certainty) |
≤ 50 | 100 | 79 | 100 | 20 | 75 | Absence of cirrhosis (F0F1F2F3) (100% certainty) |
>237 | 31 | 99 | 96 | 57 | 3 | Presence of cirrhosis (F4) (57% certainty) |